{"id":9818,"date":"2018-03-13T08:30:11","date_gmt":"2018-03-13T12:30:11","guid":{"rendered":"https:\/\/medicarereport.org\/?p=9818"},"modified":"2018-03-13T08:30:11","modified_gmt":"2018-03-13T12:30:11","slug":"amid-efforts-to-expand-naloxone-access-a-controversial-new-study-questions-its-value","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=9818","title":{"rendered":"Amid efforts to expand naloxone access, a controversial new study questions its value"},"content":{"rendered":"<p>(By Lev Facher for ST<em>A<\/em>T)<\/p>\n<p class=\"big-cap-wrap danger-zone\"><span class=\"big-cap\">WASHINGTON \u2014 Amid a worsening opioid epidemic, the overdose-reversal drug naloxone has taken center stage. Fire and police departments across the country stock the drug; nonprofits aim to get it into the hands of millions of residents as a bystander intervention. <a href=\"https:\/\/www.statnews.com\/2018\/03\/13\/naloxone-study-access\/?_hsenc=p2ANqtz-9FHliGPsYs6KDsR-s5-vwY4jOctWnObzIVnm6hZ5bMsYKUJg-Vw1hQhPe8tlfvFDudfjoBDKWLuVMDQtGFbxhRCk2IKw&amp;_hsmi=61309649\">Continue reading article here&#8230;<\/a><\/span><\/p>\n<p class=\"big-cap-wrap danger-zone\"><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>(By Lev Facher for STAT) WASHINGTON \u2014 Amid a worsening opioid epidemic, the overdose-reversal drug naloxone has taken center stage.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12,15],"tags":[],"class_list":["post-9818","post","type-post","status-publish","format-standard","hentry","category-health-care-general","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/9818","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=9818"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/9818\/revisions"}],"predecessor-version":[{"id":9819,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/9818\/revisions\/9819"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=9818"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=9818"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=9818"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}